Background
The mortality risk of patients with schizophrenia exceeds that of the general population by two to three times [
1], and cardiovascular disease is a major cause of death [
2]. Notably, a general association has been found between sudden cardiac death and diminished autonomic nervous system (ANS) activity as well as overall morbidity [
3]. Patients with schizophrenia are known to exhibit lower ANS activity compared with general populations [
4,
5] and antipsychotic medications can lead to exacerbation of ANS dysfunction [
6‐
8]. In previous studies on schizophrenia, we reported the dose-dependent manner by which antipsychotic drugs significantly decrease ANS activity [
8] as well as the dissimilar effects of different atypical antipsychotics on ANS activity, specifically that the quetiapine group showed significantly diminished sympathetic and parasympathetic activity compared with the risperidone and aripiprazole groups and significantly lower sympathetic activity relative to olanzapine [
9].
Long-acting injectable (LAI) antipsychotics are a useful option for relapse prevention, especially when patients with schizophrenia are nonadherent to their prescribed medication [
10‐
14]. A recent study reported that atypical LAI antipsychotics had the lowest risk of all-cause mortality compared with other types of antipsychotics [
15]. In addition, patients receiving atypical LAI antipsychotics had the lowest incidence of cardiovascular death among patients with schizophrenia who were receiving typical LAI antipsychotics, oral typical antipsychotic, or oral atypical antipsychotics [
15]. However, the mechanism associated with the advantage of LAI antipsychotics over oral antipsychotics in relation to cardiovascular deaths is still unclear. In particular, the effect of each atypical LAI antipsychotic on ANS activity remains to be investigated. Moreover, few studies have elucidated the differences in ANS activity between the LAI and oral formulations of the same antipsychotic.
We focused on aripiprazole because it is a representative drug for treating schizophrenia and has both oral and LAI formulations. Aripiprazole once-monthly (AOM) is a major LAI antipsychotic prescribed for schizophrenia. Aripiprazole, a second-generation antipsychotic with a high-affinity partial agonist of dopamine D2 receptors and serotonin 5-HT1A receptors and an antagonist of 5-HT2A receptors [
16], is efficacious in both the short and long term [
17], with a low incidence of side effects (e.g., weight gain and hyperprolactinemia) and metabolic adverse events, except for akathisia [
18,
19]. However, even though AOM is a major option in the treatment of schizophrenia, its effects on ANS dysfunction compared with those of oral aripiprazole are unclear and warrant further research.
In this study, we investigated the effects of oral aripiprazole and AOM on ANS activity. We noninvasively evaluated ANS activity by assessing 5-min resting heart rate variability (HRV), which can reflect autonomic nervous imbalance, in line with our previously reported work on the effects of oral atypical antipsychotics on ANS activity and their pharmacogenetic effects on ANS activity in schizophrenia [
9,
20,
21]. The reliability, validity, and practicability of HRV have been described [
22]. Understanding differences in the effects of oral and LAI aripiprazole on ANS activities could help clinicians decide which formulation to use in patients with schizophrenia.
Discussion
This study analyzed the differential effects of oral aripiprazole monotherapy and AOM monotherapy on ANS activity in patients with schizophrenia. Significant differences in HRV were evident between patients receiving oral aripiprazole and those receiving AOM, with lower LF component values seen with oral aripiprazole. These findings suggest that patients taking oral aripiprazole have diminished sympathetic nervous activity, given that the LF component indicates sympathetic and partially vagal modulation. In other words, we found that AOM was associated with less sympathetic nervous system dysfunction compared with oral aripiprazole. Indeed, in our previous small-scale preliminary study, LF component values were lower in patients receiving oral antipsychotics than in those receiving LAIs [
23]. Here, with a larger sample size, we obtained the same results in patients treated with aripiprazole monotherapy.
In recent studies, treatment-emergent adverse events resulting in the discontinuation of treatment were found to be similar in type and incidence between AOM and oral aripiprazole, and the safety and tolerability data suggested that both were well tolerated [
31,
32]. However, as pointed out by Xiao et al. [
31], several studies of psychotropic drugs have demonstrated that the risk of extrapyramidal symptom-related adverse events was lower with LAI antipsychotics than with tablets, due to the stable blood concentrations of drugs with long-acting formulations. The concentration of oral aripiprazole tends to be higher compared with the LAI equivalent [
33], and the steady-state peak-to-trough plasma concentration ratios of antipsychotics vary according to drug type, with LAI antipsychotics having lower peak-to-trough blood level variations compared with oral antipsychotics [
34,
35]. In addition, the physiochemical properties of aripiprazole lauroxil, which is a LAI prodrug of aripiprazole, result in slow dissolution and an extended pharmacokinetic profile, which affords flexibility in dose and dosing interval [
36]. A significant association has been reported and investigated between plasma concentration and an increased risk of adverse events [
37‐
39]. Moreover, a reduction in the peak concentration can mitigate the risk of dose-dependent side effects, while an increase in the trough concentration can mitigate the incidence of lack of efficacy due to subtherapeutic drug concentration [
40]. We have also reported that antipsychotic drugs affect ANS activity in a dose-dependent manner [
8]. Taken together, these factors could explain the advantage of AOM over oral aripiprazole in terms of adverse effects, such as sympathetic nervous system dysfunction.
The estimated bioavailability of AOM has been reported to be almost 48% higher than that of oral aripiprazole [
41]. LAI antipsychotics ensure better bioavailability and a more predictable correlation between drug dose and plasma concentrations, allowing lower doses to be prescribed and reducing the risk of side effects [
42]. In fact, in previous studies, the incidence of akathisia [
31] and neuroleptic malignant syndrome [
43] tended to be lower in patients receiving AOM than in those receiving oral aripiprazole. Because no previous studies had compared ANS activity between AOM and oral aripiprazole, we focused on determining whether AOM was associated with less sympathetic nervous system dysfunction than oral aripiprazole in the present study.
Notably, the advantage of AOM over oral aripiprazole in terms of treatment continuation was recently reported in the real-world clinical setting in Japan [
44]. Moreover, patients with schizophrenia who were receiving LAIs antipsychotics were found to have a lower risk of death than patients receiving oral antipsychotics [
45] and, in one analysis, the lowest incidence of cardiovascular deaths (0.17 per 1000 patient-years) was seen with atypical LAI antipsychotics [
15]. We previously reported that decreased ANS activity might be associated with all-cause mortality in patients with schizophrenia [
27], so our current finding that AOM was not associated with diminished ANS activity compared with oral aripiprazole might be associated with improved clinical safety as well as improved mortality. We did not investigate the effects of the aripiprazole formulation on treatment discontinuation or the incidence of cardiovascular death in this study and would need to monitor patients over the long term to examine those outcomes.
In multiple regression analysis, a significant association was seen between the aripiprazole formulation and the LF component related to ANS activity. The same association was found for age. However, age was unlikely to have influenced our finding that the aripiprazole formulation had different effects on sympathetic nervous system activity because there were no significant differences in age between the groups (Table
1).
This study has some limitations. First, the cross-sectional design means that causal relationships cannot be determined. Second, ANS activity might have varied due to various factors (e.g., treatment history) before the patients were assigned to the two study groups. Third, the group receiving AOM was small because we did not control for size differences in the patient groups. Fourth, trend-level differences in aripiprazole dose, anticholinergic dose, and benzodiazepine dose between the two groups might have affected the results, although multiple regression analysis showed that the drug formulation was associated with the LF component of HRV after adjusting for other clinical factors. Further studies are needed as confounding factors or small sample size might have affected the results of this study. Fifth, we evaluated drug adherence in oral aripiprazole by means of medical interviews alone. Adherence in the oral aripiprazole group might have affected the comparison between oral aripiprazole and AOM. Sixth, comparison between healthy controls and AOM was not investigated in this study. Finally, we were unable to investigate the serum and brain concentrations of aripiprazole in this study, and thus we did not evaluate the effect of changes in concentrations according to the medication time and dosing frequency of the oral drugs.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.